Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations (unaudited)

v3.21.2
Condensed Statements of Operations (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 799,779 $ 120,466 $ 2,347,564 $ 1,493,520
General and administrative 912,490 419,596 2,956,444 1,187,906
Total operating expenses 1,712,269 540,062 5,304,008 2,681,426
Loss from operations (1,712,269) (540,062) (5,304,008) (2,681,426)
Other income and expenses:        
Interest expense, net 651 57,333 45,613 158,791
Net loss (1,712,920) (597,395) (5,349,621) (2,840,217)
Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6) 269,038 0 269,038 0
Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6) 2,293,199 0 2,293,199 0
Net loss attributable to common stockholders $ (4,275,157) $ (597,395) $ (7,911,858) $ (2,840,217)
Net loss per share of common stock, basic and diluted $ (0.86) $ (0.31) $ (2.69) $ (1.49)
Weighted-average basic and diluted common units/shares 4,980,306 1,911,009 2,945,351 1,911,009